Prevention of Irinotecan Induced Diarrhea by Probiotics
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Diarrhea is a relatively common complication in patients with cancer. At its inception,
several mechanisms participated; malabsorption on the basis of mucositis induced by
chemotherapy, dysbiosis induced by broad-spectrum antibiotics and predisposition to
infectious diarrhea in immunocompromised patients. Some cytostatics and their metabolites can
also induce diarrhea directly due to effect on the intestinal mucosa.
Use of probiotics in prevention and treatment of diarrhea relies on both the theoretical
assumptions and the results of several clinical trials. Lactic acid bacteria involved in the
treatment of dysbiosis, compete for substrate with pathogenic bacteria, produce
bacterio-cins, increase transepithelial resistance. Their enzymatic activity affects
activation or deactivation of metabolites which cause diarrhea. Production of short chain
fatty acids, which are important for the maintenance of intestinal mucosal cells also
contributes to their antidiarrhoeal effect.
This randomized, double-blind, placebo controlled, multicentre trial was designed to evaluate
potential of probiotics to prevent grade 3-4 diarrhea in patients treated by irinotecan based
chemotherapy during first 6 weeks of irinotecan based chemotherapy